Proteros biostructures GmbH
http://www.proteros.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Proteros biostructures GmbH
Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
Deal Watch: AbbVie To Try Caraway’s Lysosomal Function Approach To Parkinson’s
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
More Positive Data As Decision Day Looms For AstraZeneca Lupus Drug
Competition to GlaxoSmithKline’s Benlysta in the systemic lupus erythematosus space finally looks imminent with approval decisions on AstraZeneca's anifrolumab pending. The company has presented more data at EULAR to make its case for the first-in-class type I interferon inhibitor.
Appointments: Prana, Octapharma, ABPI, Gamida and Allergy Therapeutics
This week's roundup includes senior appointments by Prana Biotechnology, Octapharma, Silence Therapeutics and ABPI, in addition to board appointments by Gamida Cell and Allergy Therapeutics.
Company Information
- Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Drug Discovery Tools
- Large Molecule